Nieves Martinez Lago MD PhD路 @DraMartinezLago 路 X路路 2 days agoScore90
Body 路 original
#ESMO26 馃殌 RASolute 302 | Phase III
馃懃 500 pts | Previously treated mPDAC
馃拪 Daraxonrasib (RAS(ON) inhibitor) vs chemo
馃搱 OS: 13.2 vs 6.7 mo (HR 0.40)
馃К OS benefit by RAS genotype:
馃敼 G12D: HR 0.49
馃敼 G12V: HR 0.32
馃敼 G12R: HR 0.61
馃搳 PFS: HR 0.55 (BICR)
馃幆 ORR: 32% vs 11%
馃挕 new SOC!
@OncoAlert
2462 views 路 39 likes 路 21 reposts 路 1 reply
Conference abstracts
LBA82matched by Proffered paper 1: Gastrointestinal tumour, upper digestive
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.orgReplies in this thread
- Mohit Kasibhatla@MohitKasibhatla
@DraMartinezLago @OncoAlert @myESMO @GrupoTTD How does 20% better RR than chemo with only 1/3 of pts responding yield a doubling in mOS? Isn鈥檛 that an outsized benefit?
Source: Nieves Martinez Lago MD PhD 路 x.com